About Merck KGaA Merck KGaA is a Germany-based science and technology company.

A Merck KGaA employee analyzes DNA fragments in an undated handout photo.

In other regions, the drug is sold by Germany's Merck KGaA.

In other regions, the drug is marketed by Germany's Merck KGaA.

The Australian Financial Review newspaper said that Sanofi-Aventis beat Merck KGaA for the unit.

Random House Inc. is a unit of Germany-based media group Bertelsmann SE & Co KGaA.

Merck KGaA sold VWR when the business was facing margin pressure and needed a cash infusion.

Aurelius Equity Opportunities SE & Co. KGaA maintains its offices in Munich, London, Madrid and Stockholm.

But that use of the drug is not included in the deal with Merck KGaA, Idera said.

The company's European partner is Merck KGaA.

Shares of Merck KGaA were down 4.3 percent in German trading.

Merck KGaA bought the development and marketing rights to Erbitux outside the United States from ImClone 10 years ago.

German-born Stefan Oschmann has been in charge of Merck & Co's emerging markets operations since 2009, Merck KGaA said.

German drugs and chemicals firms Merck KGaA and Bayer also tapped the market in 2014 for jumbo acquisition loans.

German drugs and chemicals maker Merck KGaA cut its full-year profit outlook after the company announced several one-off adjustments.

Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc's emerging markets operations.